
Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.